Table 5 Chinese Herbal Medicine for Reducing Chemotherapy Related Toxicity: Overview of Meta-Analyses Results.
First author and year of publication | Cancer cite | Comparison^ | Outcome assessment method# | No. of studies (No. of patients) | Pooled results (95%CI)¶ | Heterogeneity I2 (%) | Quality of evidence |
|---|---|---|---|---|---|---|---|
Leucopenia | |||||||
Wu,2009a | NSCLC | Aidi injection + NP vs. NP | Grade II–IV | 13 (1000) | RR: 0.59[0.52, 0.67] | NR | Low |
Dong,2010b | NSCLC | SFI+ platinum containing chemotherapy vs. platinum containing chemotherapy | Grade III–IV | 20(1643) | RR: 0.37[0.29, 0.47] | 0.0 | Moderate |
Li, 2013 | NSCLC | CHM+ chemotherapy vs. chemotherapy | Grade III–IV | 9(666) | RR: 0.36[0.26, 0.52] | 0.0 | Moderate |
CHM+ chemotherapy vs. chemotherapy | Grade I–IV | 8(603) | RR: 0.75[0.67, 0.84] | 20.0, | Moderate | ||
Xu, 2014 | NSCLC | KLT+ chemotherapy vs. chemotherapy | Grade III–IV | 10(982) | OR: 0.54[0.38, 0.77] | 52.0* | Moderate |
Liu,2009 | CRC | CHM+ chemotherapy vs. chemotherapy | Grade I | 6(334) | RR: 0.50[0.31, 0.80] | 7.0 | Moderate |
CHM+ chemotherapy vs. chemotherapy | Grade II | 6(334) | RR: 0.37[0.21, 0.66] | 0.0 | Low | ||
CHM+ chemotherapy vs. chemotherapy | Grade III | 5(281) | RR: 0.47[0.19, 1.19] | 0.0 | Low | ||
CHM+ chemotherapy vs. chemotherapy | Grade IV | 2(129) | RR: 0.13[0.02, 1.05] | 0.0 | Low | ||
Chen, 2014 | CRC | CHM+FOLFOX4 vs. FOLFOX4 | Neutropenia grade III–IV | 10(692) | RR: 0.33[0.18, 0.60] | 0.0 | Low |
Shi, 2012 | Gastric cancer | CHM+ chemotherapy vs. chemotherapy | Grade II–IV | 7(353) | OR: 0.26[0.18, 0.37] | 35.0 | Moderate |
Dong, 2010a | Various | Astragalus injection + chemotherapy vs. chemotherapy | Grade I–IV | 9(927) | RR: 0.84 [0.79, 0.88] | 77.3* | Low |
Fu, 2010 | Various | CHM+ chemotherapy vs. chemotherapy | Grade I–IV | 11(2169) | OR: 0.40 [0.23, 0.68] | 55.0* | Moderate |
Nausea and vomiting | |||||||
Wu, 2009a | NSCLC | Aidi injection + NP vs. NP | Grade II–IV | 10 (781) | RR: 0.52[0.43, 0.62] | NR | Low |
Dong, 2010b | NSCLC | SFI+ platinum containing chemotherapy vs. platinum containing chemotherapy | Grade III–IV | 14(1031) | RR: 0.32[0.22, 0.47] | 0.0 | Moderate |
Li, 2013 | NSCLC | CHM+ chemotherapy vs. chemotherapy | Grade III–IV | 4(295) | RR: 0.24[0.12, 0.50] | 0.0 | Moderate |
Xu, 2014 | NSCLC | KLT+ chemotherapy vs. chemotherapy | Grade III–IV | 10(982) | OR: 0.54[0.38, 0.77] | 52.0* | Moderate |
Li, 2012b | Liver cancer | CHM+TACE vs. TACE alone or TACE+ conventional care | Grade I–IV | 11(816) | RR: 0.79[0.69, 0.91] | 48.0* | Moderate |
Cheung, 2013 | Liver cancer | CHM+TACE vs. TACE | Grade I–IV | 9(581) | RR: 0.86 [0.76, 0.96] | 40.0 | Moderate |
Liu, 2009 | CRC | CHM+ chemotherapy vs. chemotherapy | Grade I | 6(334) | RR: 0.85 [0.60, 1.20] | 0.0 | Moderate |
CHM+ chemotherapy vs. chemotherapy | Grade II | 6(334) | RR: 0.51 [0.31, 0.84] | 0.0 | Moderate | ||
CHM+ chemotherapy vs. chemotherapy | Grade III | 6(334) | RR: 0.49 [0.23, 1.05] | 0.0 | Moderate | ||
CHM+ chemotherapy vs. chemotherapy | Grade IV | 1(61) | RR: 0.11 [0.01, 1.92] | NA | Very low | ||
Chen, 2014 | CRC | CHM+FOLFOX4 vs. FOLFOX4 | Grade III–IV | 9(633) | RR: 0.34[0.18, 0.66] | 0.0 | Moderate |
Shi, 2012 | Gastric cancer | CHM+ chemotherapy vs. chemotherapy | Grade II–IV | 5(279) | OR: 0.48[0.34, 0.66] | 0.0 | Moderate |
Thrombocytopenia | |||||||
Dong, 2010b | NSCLC | SFI+ platinum containing chemotherapy vs. platinum containing chemotherapy | Grade III–IV | 18(1335) | RR: 0.33[0.21, 0.52] | 0.0 | Moderate |
Li, 2013 | NSCLC | CHM+ chemotherapy vs. chemotherapy | Grade III–IV | 6(557) | RR: 0.34[0.17, 0.68] | 0.0 | Moderate |
CHM+ chemotherapy vs. chemotherapy | Grade I–IV | 6(494) | RR: 0.43[0.31, 0.60] | 0.0 | Moderate | ||
Chen, 2014 | CRC | CHM+FOLFOX4 vs. FOLFOX4 | Grade III–IV | 1(42) | RR: 1.00[0.07, 14.95] | NA | Moderate |
Shi, 2012 | Gastric cancer | CHM+ chemotherapy vs. chemotherapy | Grade II–IV | 4(225) | OR: 0.35[0.14, 0.86] | 0.0 | Moderate |
Dong, 2010a | Various | Astragalus + chemotherapy vs. chemotherapy | Grade I–IV | 8(829) | RR: 0.69 [0.56, 0.85] | 83.5* | Moderate |
Fu, 2010 | Various | CHM+ chemotherapy vs. chemotherapy | Grade I–IV | 7(1162) | OR: 0.41 [0.27, 0.62] | 8.9 | Moderate |
Anemia | |||||||
Dong, 2010b | NSCLC | SFI+ platinum containing chemotherapy vs. platinum containing chemotherapy | Grade III–IV | 15(1161) | RR: 0.44[0.30, 0.66] | 0.0 | Moderate |
Li, 2013 | NSCLC | CHM+ chemotherapy vs. chemotherapy | Grade I–IV | 6(553) | RR: 0.64[0.51, 0.80] | 25.0 | Moderate |
CHM+ chemotherapy vs. chemotherapy | Grade III–IV | 6(536) | RR: 0.58[0.26, 1.29] | 0.0 | Moderate | ||
Chen, 2014 | CRC | CHM+FOLFOX4 vs. FOLFOX4 | Grade III–IV | 3(220) | RR: 0.30[0.05, 1.89] | 0.0 | Low |
Shi, 2012 | Gastric cancer | CHM+ chemotherapy vs. chemotherapy | Grade II–IV | 4(207) | OR: 0.38[0.25, 0.58] | 43.0 | Moderate |
Dong, 2010a | Various | Astragalus+ chemotherapy vs. chemotherapy | Grade I–IV | 4(371) | RR: 0.42 [0.27, 0.65] | 33.1 | Moderate |
Neurotoxicity | |||||||
Liu,2009 | CRC | CHM+ chemotherapy vs. chemotherapy | Grade I | 5(273) | RR: 0.84 [0.57, 1.24] | 0.0 | Low |
CHM+ chemotherapy vs. chemotherapy | Grade II | 5(273) | RR: 0.73 [0.45, 1.19] | 0.0 | Low | ||
CHM+ chemotherapy vs. chemotherapy | Grade III | 5(273) | RR: 0.40 [0.13, 1.25] | 0.0 | Low | ||
Chen, 2014 | CRC | CHM+FOLFOX4 vs. FOLFOX4 | Grade III–IV | 7(529) | RR: 0.39[0.15, 1.00] | 0.0 | Low |
Other chemotherapy related toxicity | |||||||
Chen, 2014 | CRC | CHM+FOLFOX4 vs. FOLFOX4 | Diarrhea grade III–IV | 5(448) | RR: 0.39[0.11, 1.42] | 0.0 | Low |
CHM+FOLFOX4 vs. FOLFOX4 | Stomatitis grade III–IV | 2(210) | RR: 0.43[0.08, 2.31] | 0.0 | Low | ||
